Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from VRTX

3 Pharma Stocks to Watch as Gene Therapy Gains Momentum

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and improve treatment options. Given this favorable trend, it could be wise to watch strong pharma stocks such as Vertex Pharmaceuticals (VRTX), Wave Life Sciences (WVE), and Poseida Therapeutics (PSTX). Read more.

StockNews.com

What You Need to Know Ahead of Vertex Pharmaceuticals' Earnings Release

Vertex Pharmaceuticals will unveil its Q3 earnings next month, and analysts project a lower-single-digit bottom-line growth.

Barchart

Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?

Vertex Pharmaceuticals has outperformed the Nasdaq over the past year, and analysts remain moderately bullish about the stock's prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Are Wall Street Analysts Bullish on Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has outperformed the broader market in 2024 but Wall Street analysts remain cautiously bullish about the stock's potential.

Barchart

3 Gene-Editing Stocks to Buy for Future Health Advances

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

StockNews.com

3 Biotech Stocks With Revolutionary Pipelines to Buy Today

The biotech industry is experiencing rapid growth owing to new drug innovations and advancements in healthcare. To capitalize on the industry's expansion, it could be wise to invest in solid biotech stocks, Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD), which have revolutionary pipelines. Read on….

StockNews.com

What to Expect From Vertex Pharmaceuticals’ Next Quarterly Earnings Report

Vertex Pharmaceuticals will unveil its Q2 earnings next month, and analysts project a single-digit bottom-line growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Is Vertex Stock Outperforming the S&P 500?

Vertex has outperformed the S&P 500 over the past year, and analysts are moderately bullish on the stock.

Barchart

3 Popular Biotech Stocks Offering Solid June Returns

The biotech industry is poised for significant growth due to the rising orphan drug formulations and the surging popularity of plant-based products. Hence, quality biotech stocks, Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Jazz Pharmaceuticals (JAZZ) could be ideal investments for solid returns. Read more….

StockNews.com

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

Investors Business Daily

Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?

After a solid first-quarter earnings report, Vertex Pharmaceuticals (VRTX) comfortably topped analysts’ earnings and revenue estimates in the first quarter. But should investors consider adding the stock to their portfolio now? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

3 Biotech Stocks to Invest In Right Now for Long-Term Gains

With the rapidly growing demand for personalized medicine, innovative solutions, and recent developments like AI in drug discovery, the biotech industry's prospects appear robust. Thus, quality biotech stocks Vertex Pharmaceuticals (VRTX), SIGA Technologies (SIGA), and Gilead Sciences (GILD) could be ideal candidates to buy now. Read more….

StockNews.com

Top Biotech 3 Stocks With Accelerating Profits

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….

StockNews.com

Jumpstart Your Portfolio With These 3 Biotech Stocks

The biotech industry’s robust growth potential is fueled by scientific advancements, rapid technological adoption, and supportive government initiatives. Thus, you could consider investing in top biotech stocks Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Vanda Pharmaceuticals (VNDA) to strengthen your portfolio. Keep reading….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Three S&P 500 Giants Lead This List Of Stocks Near Buy Points

S&P 500 stocks Lennar, Vertex Pharmaceuticals and Royal Caribbean lead this list of five stocks trading around buy points.

Investors Business Daily

Here's Why IBD Stock Of The Day Vertex Pharmaceuticals Is Newly Actionable

Vertex is the IBD Stock Of The Day. VRTX stock bounced off its 50-day line as investors watch for the first sales of its gene-editing drug.

Barchart

This Could Be the Next Blockbuster Drug Stock to Buy

Vertex Pharmaceuticals just released data from its experimental drug to relieve pain, with no risk of addiction and very few side effects. This opioid alternative could give Vertex - already a powerhouse in the cystic fibrosis segment - another blockbuster drug to add to its portfolio.

StockNews.com

Dominate the Market With 3 Biotech Stocks

The biotech industry’s growth prospects look promising due to considerable investments in research and development (R&D), an innovative drugs pipeline, government initiatives, the growing popularity of personalized medicine, drug approvals, expanding healthcare needs, etc. Amid this backdrop, investors could consider buying fundamentally strong biotech stocks Innoviva (INVA), Foghorn Therapeutics (FHTX),…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Why Investors Are Flocking to These 2 Medical Stocks

Given the growing demand for healthcare facilities, rapid integration of digital technology, and transformative biotechnology breakthroughs, the medical industry is poised for continued growth and profitability this year and beyond. Amid this, let’s find out why investors are flocking to medical stocks Vertex Pharmaceuticals (VRTX) and McKesson (MCK). Read more….

Investors Business Daily

Vertex Is Trying To Replace Its Biggest Drug — Does It Stand A Chance?

Vertex could bolster its cystic fibrosis franchise with a next-generation drug, analysts said Tuesday. But VRTX stock dipped.

StockNews.com

Analyzing 3 Biotech Stocks for 2024 Gain Potential

With technology revolutionizing drug discovery, the biotech sector thrives on innovation and breakthrough therapies. Hence, let's delve into and analyze the gain potential of fundamentally strong biotech stocks Amgen (AMGN), Alkermes (ALKS), and Vertex Pharmaceuticals (VRTX). Read more….

Investors Business Daily

Vertex Rebounds — But Its Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst

Vertex's alternative to opioids is "not a game-changer," an analyst said Tuesday. But VRTX stock rebounded on the company's test results.

StockNews.com

3 Lucrative Biotech Stock Buys for Success

The development of orphan medications, innovative biotech equipment, personalized medicine, and strong government support are all contributing to the biotech industry's upward trajectory. Thus, lucrative biotech stocks Vertex Pharmaceuticals (VRTX), Innoviva (INVA), and Organogenesis Holdings (ORGO) could be ideal additions to your portfolio right now. Read more….

Investors Business Daily

Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock

Crispr won its second gene-editing approval on Tuesday — two months ahead of time. But CRSP stock slipped, and VRTX stock rose minimally.

Barchart

3 Iron Condor Trade Ideas For January 5th

Volatility is on the rise which could mean it’s a good time to be on look lookout for Iron Condor trades.

1 2 3 4 5

People

Dipanjan BanchurSince

722 stories

Kritika SarmahHer

680 stories

Mangeet Kaur BounsMangeet

595 stories

Brian Abrahams

53 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.